Cancer Control at the Intersection of Aging Research

衰老研究交叉点的癌症控制

• 批准号: 6642715
• 负责人: Jeanne Mandelblatt
• 金额: $ 13.86万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-16 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6642715
• 关键词: aging; behavioral /social science research tag; breast neoplasms; cancer information system; clinical research; comorbidity; decision making; disease /disorder etiology; female; health care quality; health economics; human old age (65+); human subject; interview; medically underserved population; neoplasm /cancer chemotherapy; outcomes research; patient care personnel relations; preference; prejudice; quality of life; satisfaction; statistics /biometry; women's health

DESCRIPTION (provided by applicant): Dr. Mandelblatt is a geriatrician with health services and epidemiology training. She is currently Director of Cancer Control at Lombardi Cancer Center. Dr. Mandelblatt has a long history of continuous peer-reviewed funding almost $31 million and centered on translational research for individuals 65 years and older (hereinafter referred to as "elderly" or "older"). Dr. Mandelblatt's focus on understanding and eliminating age and race disparities in cancer care miletus national priorities. For instance, the US Department of Health and Human Services (DHHS) has recently renewed its "war on cancer" by declaring the elimination of age (and race) disparities as a key priority. The National Cancer Institute Year 2010 goals echo this priority. The importance of these national cancer control objectives is cast on the backdrop of the changing demographic profile of the US: by the year 2030, one in five will be elderly and 40 percent will be from minority groups. Despite this "demographic imperative" and rising cancer rates with advancing age, there is a shortage of researchers trained to address the needs of diverse older populations. Dr. Mandelblatt is one a small cadre of scientists in the US with this expertise. One important cancer care gap, recently identified by the Institute of Medicine, is under use of chemotherapy. However, we know little about treatment decision making in regional breast cancer, where chemotherapy can have substantial benefits. Moreover, there is a paucity of data on quality of life and clinical outcomes of therapy in older women. Chemotherapy decision making is particularly complex for older women owing to limited age-related data on cancer biology, potential treatment toxicity, interactions of treatment and comorbidity, limitations in physical, social, and economic resources, and possible biases in care delivery. The research and mentoring proposed in this application will address these issues. The specific objectives proposed for this award are threefold: (1) To conduct theory-based research on patient preferences and clinical characteristics affecting decisions about use of systemic non-hormonal chemotherapy in older women with regional breast cancer, (2) To develop a research database infrastructure to conduct new studies about potential race and age-related biases in care, and (3) To develop a training infrastructure to develop young investigators in population sciences, behavioral research, and cancer control for older individuals. With this award, Dr. Mandelblatt will be able to continue her commitment to gero-oncology, have sufficient protected time to train new investigators in this nascent field, and address new research innovations to advance the science of cancer control at the intersection of aging.

描述（由申请人提供）：Mandelblatt博士是一名老年医生，接受了健康服务和流行病学培训。 她目前是伦巴第癌中心的癌症控制主管。 曼德尔布拉特（Mandelblatt）博士在持续的同行评审资金近3100万美元的悠久历史上，集中于65岁及65岁以上个人的转化研究（以下称为“老年人”或“年龄较大”）。 Mandelblatt博士专注于理解和消除癌症护理米利特斯国家优先事项的年龄和种族差异。 例如，美国卫生与公共服务部（DHHS）最近通过宣布消除年龄（和种族）差距为重点，从而恢复了“癌症战争”。 2010年国家癌症研究所的目标与此优先级相呼应。 这些国家癌症控制目标的重要性是在不断变化的美国人口概况的背景下进行的：到2030年，五分之一将是老年人，而40％的人将来自少数群体。 尽管随着年龄的增长，尽管有这种“人口统计学势在必行”和癌症率上升，但仍有研究人员缺乏满足不同老年人群需求的培训。 曼德尔布拉特博士是美国科学家的一小部分，具有这种专业知识。 医学研究所最近确定的一个重要的癌症护理差距正在化学疗法中使用。 但是，我们对区域乳腺癌的治疗决策知之甚少，在该区域乳腺癌中，化学疗法可以带来可观的好处。 此外，关于老年妇女的生活质量和治疗临床结果的数据很少。 由于与年龄相关的癌症生物学，潜在的治疗毒性，治疗和合并症的相互作用，物理，社会和经济资源的限制以及医疗服务的可能偏见，化学疗法决策对于老年妇女特别复杂。 本应用程序中提出的研究和指导将解决这些问题。 该奖项提出的具体目标是三重：（1）对患者偏好和临床特征进行基于理论的研究，这些研究影响了有关使用全身性非荷尔蒙化学疗法的决策，（（2）开发研究数据库基础设施，以开发针对潜在的种族和年龄研究的新研究，以开发培训的新研究，并（3）开发了培训，并开发了（3）培训，以及（3）培训，（3）培训率（3）培训，以及（3）培训，（3）和对老年人的癌症控制。 有了这个奖项，曼德尔布拉特博士将能够继续她对Gero-Oncology的承诺，有足够的保护时间在这个新生的领域培训新的研究人员，并介绍了新的研究创新，以在衰老交叉口促进癌症控制科学。